December 1, 2021
Astellas Pharma launched its antibody-drug conjugate (ADC) Padcev (enfortumab vedotin) in Japan on November 30 for the treatment of certain patients with urothelial cancer, the most common type of bladder cancer. The drug is approved for an indication of radically...read more